Resources Repository
-
ArticlePublication 2022COVID-19 Response: The Need for Economic Evaluation
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be …
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be quantitatively weighed using economic evaluation, such as those between health and cost outcomes. Other types of dimensions, such as those involving equity or autonomy, can be harder to quantify but should be considered in a comprehensive health policy decision-making context nonetheless. The authors of this New England Journal of Medicine Perspectives article outline how methods of economic evaluation and decision…
Benefit-Cost Analysis | Policy/Regulation | Priority Setting/Ethics | Cost-Effectiveness Analysis | Infectious Diseases | Economics/Finance | Health/Medicine | Global | North America -
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
Benefit-Cost Analysis | Policy/Regulation | Value of Information | State-Transition | Infectious Diseases | Economics/Finance | North America | Europe -
ReportPublication 2021Valuing COVID-19 Mortality and Morbidity Risks
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk …
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk reductions that builds on the U.S. Department of Health and Human Services (HHS) Guidelines for Regulatory Impact Analysis. They review the differences between COVID-19 mortality risks and the types of risks that are more commonly studied, and find that the impacts of these differences on the value of mortality risk reductions (the value per statistical life, VSL) are uncertain. They…
Benefit-Cost Analysis | Policy/Regulation | Preferences/Values | Infectious Diseases | Government/Law | North America -
ArticlePublication 2021Individual and Social Determinants of COVID-19 Vaccine Uptake
This article examined the individual, communication and social determinants associated with COVID-19 vaccine uptake using …
This article examined the individual, communication and social determinants associated with COVID-19 vaccine uptake using national survey data collected before vaccines were available in the U.S. Of note, individuals under the federal poverty level and racial and ethnic minorities were oversampled. Outcomes included the likelihood of vaccinating self and dependents (e.g., children). Independent variables included perceptions of risk, exposure to different media for COVID-19 news, political party identification, confidence in scientists and social determinants of…
Evidence Synthesis | Policy/Regulation | Health Outcomes | Infectious Diseases | Social Determinants | Clinical Care | Culture/Society | Health/Medicine | Science/Technology | North America -
ArticlePublication 2021Health Opportunity Cost Threshold for CEA in the U.S.
Using a modeled cohort of 100,000 individuals in the United States with private health insurance, …
Using a modeled cohort of 100,000 individuals in the United States with private health insurance, the authors simulated the short-term mortality and morbidity resulting from increased premium related cancelation of insurance coverage. The authors used this model to estimate cost-effectiveness thresholds, in dollars per quality-adjusted life year (QALY) gained based on health opportunity costs. They reported the number of persons who dropped insurance coverage, resulting number of additional deaths and QALYs lost from mortality and…
Evidence Synthesis | Policy/Regulation | Priority Setting/Ethics | Health Outcomes | Microsimulation | Cost-Effectiveness Analysis | Health Systems | Health/Medicine | North America -
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Technology Assessment | Policy/Regulation | Probability/Bayes | Test Performance | Infectious Diseases | Health Systems | Government/Law | Health/Medicine | Global | North America -
Resource PackPublication, Teaching Resource 2020Resource Pack: Cost-Effectiveness of SSB Excise Taxes
The use of fiscal instruments, such as taxes or subsidies, to promote healthier dietary behavior …
The use of fiscal instruments, such as taxes or subsidies, to promote healthier dietary behavior has been of increasing interest in the last decade as the evidence-base builds for the health and economic consequences of obesity, overweight, and unhealthy eating. The motivation for using fiscal instruments in nutrition policy is to make the unhealthy option less affordable and less economically attractive by increasing the price via a tax, and therefore reduce the incentive to consume…
Evidence Synthesis | Policy/Regulation | Health Outcomes | Mathematical Models | Microsimulation | Cost-Effectiveness Analysis | Child/Nutrition | Chronic Disease/Risk | Business/Industry | Economics/Finance | Food/Agriculture | Government/Law | Health/Medicine | North America | Latin America & Caribbean | Europe | Oceania -
Resource PackPublication, Teaching Resource 2021Resource Pack: Valuing Health and Longevity in BCA
This resource pack, curated by the Center for Health Decision Science, introduces the valuation of …
This resource pack, curated by the Center for Health Decision Science, introduces the valuation of changes in health and longevity in benefit-cost analysis. It is targeted towards advanced students and practitioners who have a basic understanding of the benefit-cost analysis framework, as discussed in the Resource Pack: Introduction to Benefit-Cost Analysis. That pack provides a general overview of the approaches that are explored in more detail here, as well as related guidance documents. This pack…
Benefit-Cost Analysis | Policy/Regulation | Preferences/Values | College | Graduate | Critical Thinking/Analysis | Policy Translation -
Online LearningVideo, Teaching Resource 2020Valuing Statistical Lives: Concepts, Current Practices, and Challenges
Many policies aim to improve longevity, decreasing the risk of death in each year, and …
Many policies aim to improve longevity, decreasing the risk of death in each year, and the value of these risk reductions often dominate the estimated benefits of risk regulations and other policies. This value is often expressed as the value per statistical life (VSL), a term that is widely misunderstood. It is not the value that the analyst, the government, or the individual places on saving an identified life with certainty. Instead, it reflects individuals’…
Benefit-Cost Analysis | Policy/Regulation | Climate/Environment | Health/Medicine | Global